6288-63-7

Basic information

• Product Name: N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE
• Synonyms: N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE;N-(2-chloroethyl)benzylamine hydrochloride;Benzenemethanamine, N-(2-chloroethyl)-, hydrochloride (9CI);N-BENZYL-N-(2-CHLOROETHYL)AMINEHYDROCHLORIDE;N-(2-CHLOROETHYL)-BENZYLAMINE HCL;N-BENZYL-2-CHLOROETHANAMINE HCL
• CAS NO: 6288-63-7
• Molecular Formula: C₉H₁₂ClN*ClH
• Molecular Weight: 206.11222
• EINECS: 228-525-2
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 6288-63-7.mol

Chemical Properties

• Boiling Point: 245.1°C at 760 mmHg
• Flash Point: 102.1°C
• Appearance: /
• Density: 1.067g/cm³
• Vapor Pressure: 0.0292mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE(6288-63-7)
• EPA Substance Registry System: N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE(6288-63-7)

Safety Data

• Hazardous Substances Data: 6288-63-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE is used as a building block for the creation of a wide range of organic compounds, leveraging its unique structural features to form novel chemical entities with specific properties and functions.
Used in Chemical Research:
N-BENZYL-2-CHLOROETHANAMINE HYDROCHLORIDE is employed as a research tool in chemical laboratories to study the reactivity and properties of organic amines, particularly those with benzyl and chlorine substituents, contributing to the advancement of chemical knowledge and the discovery of new chemical reactions and processes.

InChI:InChI=1/C9H12ClN/c10-6-7-11-8-9-4-2-1-3-5-9/h1-5,11H,6-8H2

Upstream product

• 104-63-2 N-Benzylethanolamine 

Downstream Products

• 29824-06-4 bis-(2-benzylamino-ethyl)-disulfide 
• 122958-19-4 2-[4-(1H-Imidazol-1-yl)phenyloxy]-N-(phenylmethyl)ethanamine 
• 118107-85-0 N-Benzyl-N'-phenyl-1,2-diaminoethane hydrochloride 
• 1271436-27-1 N-benzyl-N-(2-chloroethyl)isonicotinamide 
• 134296-11-0 N-benzyl-2-(diphenylphosphaneyl)ethan-1-amine 
• 118107-87-2 4-(2-Benzylamino-ethylamino)-benzoic acid ethyl ester; hydrochloride 
• 118107-89-4 N-Benzyl-N'-(2,6-dimethyl-phenyl)-ethane-1,2-diamine; hydrochloride 
• 118116-73-7 N-Benzyl-N'-(4-methoxy-phenyl)-ethane-1,2-diamine; hydrochloride 
• 118107-86-1 N-Benzyl-N'-(4-chloro-phenyl)-ethane-1,2-diamine; hydrochloride 
• 118107-88-3 4-(2-Benzylamino-ethylamino)-phenol; hydrochloride 

Relevant articles and documents

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Control of aminophosphine chelate ring-opening in Pt(II) and Pd(II) complexes: Potential dual-mode anticancer agents

We show that bis(aminophosphine) complexes of the type [M(R1R2N(CH2)nPPh2)2 ]2+, M = Pt(II) or Pd(II), can exist in chelate ring-closed and ring-opened forms both in the solid state and in aqueous solution. The equilibrium between them in solution can be controlled by the nature of the groups R1 and R2 (H, Me, Bz, cyclohexyl), by the bridge length n, and by the pH and Cl- concentration. X-Ray crystal structures are reported for the ring-closed complexes cis-[Pt(H2N(CH2)2PPh2-P,N)2 ]Cl2, cis-[Pt(H2N(CH2)3PPh2-P,N)2 ]Cl2, and cis-[Pt(Me(H)N(CH2)2PPh2-P,N)2][HCl 2]2, the mono-ring-opened complex cis-[Pd(Me2N(CH2)2PPh2-N,P)Cl(Me 2NH(CH2)2PPh2-P)](NO3) 2, the di-ring-opened complex cis-[Pt(Me2N(CH2)3PPh2-P)2 CL2], and, for comparison, the monochelate cis-[Pd(Me2N(CH2)3PPh2-N,P)CL2 ]. These square-planar complexes exhibit varying degrees of distortion and variable M-N bond lengths dependent not only on the trans influence of P but also on steric effects within the complex, pH-induced chelate ring-opening of cis-[Pt(Me2N(CH2)2PPh2-P,N)2 ]CL2 had an associated pK value of 6.9. In contrast, complexes with R1 and R2 = H, n = 2 or 3 or R1 = H and R2 = Me, n = 2, are more difficult to ring-open. Thus the complexes cis-[Pt(Me(H)N(CH2)2-PPh2-P,N)2]CL 2 and cis-[Pt(H2N(CH2)3PPh2-P,N)2 ]CL2, had associated pK values of 2.1 and 2.9, respectively. These aminophosphine complexes may exhibit anticancer activity by two mechanisms: by disrupting mitochondrial membrane potentials as bis-chelated (ring-closed) lipophilic cations, or by direct binding to DNA bases as ring-opened complexes.

Synthesis and characterisation of β-aminophosphine ligands on a solid support

Synthesis and characterization of β-aminophosphine ligands on a solid support was described. An assessment strategy combining complementary on-resin characterization techniques demonstrated the yield and purity of the support-bound ligands. The combination of the applied synthetic and analytical methods represented an innovative and general approach to the solid-phase synthesis of phosphorus ligands.

PIPERAZINE OXYTOCIN RECEPTOR ANTAGONISTS

This invention relates to certain novel piperazine compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These componds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha 1a adrenergic receptor antagonist

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Tocolytic oxytocin receptor antagonists

Compounds of the formula X--Y--R, or the pharmaceutically acceptable salts and esters thereof, wherein X is STR1 Y is --SO2 --, --(CH2)p -- or --CO--(CH2)p --; R is unsubstituted or substituted phenyl where said substitutents are one or more of R5, R6 or R7 ; R1 is hydrogen, cyano, phenyl,--CONHR2, --CONR2 R2, --(CH2)m --OR2, --(CH2)p --S(O)r --R2, --(CH2)m --CO2 R2, --(CH2)m --N3, --(CH2)m --NH2 or --(CH2)m --NR2 R2 ; R2 is hydrogen, C3-8 cycloalkyl or C1-5 alkyl; R5 and R6 are each independently selected from hydrogen, C1-5 alkoxy, halogen or --(CH2)n --N(R2)--C(O)--R18 ; R7 is hydrogen or STR2 R11 is selected from hydrogen, C1-5 alkylcarbonyl, STR3 or substituted C1-5 alkyl wherein said alkyl substituent is unsubstituted, mono-, di- or tri-substituted pyridyl wherein said substitutents on said pyridyl are independently selected from halogen, C1-5 alkyl or C1-5 alkoxyl; R13 is unsubstituted or substituted C1-10 alkyl wherein the substituent is selected from --N(R2)2, --NHR2 or imidazolyl; R14 and R15 are each independently selected from C1-5 alkyl, C1-5 alkoxy or halogen; R16 is hydrogen or oxo; R18 is C1-5 alkoxyl, unsubstituted or substituted C1-5 alkyl where said substituent is Het, unsubstituted or substituted C2-5 alkenyl where said subsituent is Het or Het; Het is benzimidazolyl, carboxymethyl-substituted benzimidazolyl or indolyl; m is an integer of from 1 to 5; p is an integer of from 1 to 3; and r is an integer of from 0 to 2. Such compounds as useful as oxytocin and vasopressin receptor antagonists.

Mercaptoacylpiperazine carboxylic acid compounds

The mercaptoacylpiperazine carboxylic acid compounds which have the formula STR1 wherein R, R3 and R4 each is hydrogen or lower alkyl; R1 is lower alkyl; R2 is hydrogen, lower alkanoyl, benzoyl or STR2 m is 0, 1 or 2; n is 1, 2 or 3, the sum of m+n being equal to 1, 2 or 3 and salts thereof, are useful as hypotensive agents.